Please login to the form below

Not currently logged in


This page shows the latest Ionis news and features for those working in and with pharma, biotech and healthcare.

AZ makes gene therapy move with 4DMT alliance

AZ makes gene therapy move with 4DMT alliance

also working with Ionis on antisense drugs for a range of targets including a nonalcoholic steatohepatitis (NASH) candidate that was the subject of a $300m licensing deal in April.

Latest news

More from news
Approximately 9 fully matching, plus 15 partially matching documents found.

Latest Intelligence

  • Deal Watch February 2017 Deal Watch February 2017

    Ionis has recently received a $75m milestone payment from Bayer having successfully completed a phase II study on IONIS-FXIRx in patients with end-stage renal disease on haemodialysis. ... As part of the agreement Ionis will also expand the collaboration

  • Deal Watch January 2017 Deal Watch January 2017

    As you sow, so shall you reap The use of options is remaining widespread as noted in the Novartis deal with Ionis and Akcea. ... 1, 700. Ionis | Akcea. Novartis. Exclusive option to licence. AKCEA-APOCIII-LRx for heart failure.

  • Deal Watch August 2016 Deal Watch August 2016

    95. Ionis (US). Biogen (US). Exercise option . Nusinersen, in phase III for treatment for spinal muscular atrophy.

  • Deal Watch May 2016 Deal Watch May 2016

    This month GSK elected not to currently proceed with its option to Ionis Pharmaceuticals' IONIS-TTRrx, which was about to enter into phase 3 clinical development. ... The knock on effect for Ionis shares was a dip by a significant 40%.

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Cuttsy + Cuttsy

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Latest intelligence

GDPR and events. What does the pharma industry need to know?
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...